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Abstract
Introduction: Interleukin-6 (IL-6) is a pleiotropic cytokine which signals through a cell surface receptor complex consisting of a cognate 
receptor subunit (IL-6R) and glycoprotein 130 (gp130), which is considered an antagonist to the IL-6R/IL-6 pathway. The aim of the present 
study was to assess IL-6/IL-6R/gp130 system and Th17 associated cytokines in different time points during and after pregnancy in women 
with gestational diabetes mellitus (GDM) and normal glucose tolerance (NGT).
Material and methods: Serum levels of IL-6, sIL6R, sgp130, IL-17 and IL-23 were measured in 91 women divided into three groups: GDM 
in the 24th–28th week of gestation (visit 1), NGT at the 1st visit and GDM in the 29th-32nd week, and NGT at both visits. 
Results: The patients with GDM recognised at the 1st visit had significantly higher IL-6 (p = 0.02) and sgp130 (p = 0.03) concentra-
tions than had the women with NGT, whereas the women with GDM diagnosed at the 2nd visit had elevated sIL-6R concentrations 
(p = 0.03). The patients with low sIL-6R but high sgp130 concentration had significantly higher glucose levels (p = 0.04) and lower IL-6 values 
(p = 0.04) than had the patients with low sIL-6R and sgp130 concentrations. IL-17 and IL-23 were detected in approximately one-third of the 
population studied. A trend towards higher IL-17 levels was observed in the subjects with GDM, but the differences were not significant.
Conclusions: Our results suggest that an increased serum sgp130 concentration in the patients with GDM might represent a compensatory 
mechanism, controlling intracellular IL-6 signalling and preventing the activation of the IL-6/IL-6R pathway. (Endokrynol Pol 2014; 65 (3): 169–175)
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Streszczenie
Wstęp: Interleukina-6 (IL-6) jest plejotropową cytokiną, która przekazuje sygnał do wnętrza komórki za pośrednictwem receptora bło-
nowego złożonego z właściwej podjednostki receptorowej (Il-6R) i glikoproteiny 130 (gp130), uważanej za antagonistę kompleksu IL-6R/ 
/IL-6. Celem pracy była analiza szlaku IL-6/IL-6R/gp130 i cytokin zależnych od limfocytów Th17 w II i III trymestrze ciąży oraz po porodzie 
u pacjentek z cukrzycą ciążową i prawidłową tolerancją glukozy.
Materiał i metody: Dokonano pomiaru stężenia IL-6, IL6R, gp130, IL-17 i IL-23 w surowicy 91 kobiet podzielonych na 3 podgrupy: 
pacjentki z cukrzycą ciążową zdiagnozowaną w 24.–28. tygodniu ciąży (wizyta 1), pacjentki z prawidłową tolerancją glukozy w trakcie 
1 wizyty i cukrzycą ciążową rozpoznaną w 29.–32. tygodniu ciąży oraz pacjentki z prawidłową tolerancją glukozy w trakcie obu wizyt.
Wyniki: U pacjentek z cukrzycą ciążową rozpoznaną w trakcie 1 wizyty wykazano istotnie wyższe stężenia IL-6 (p = 0,02) i gp130 
(p = 0,03) w porównaniu z kobietami z prawidłową tolerancją glukozy, podczas gdy pacjentki z cukrzycą ciążową rozpoznaną w trakcie 
2 wizyty charakteryzowały się wyższym stężeniem IL-6R (p = 0,03). U pacjentek z niskim stężeniem IL-6R i wysokim stężeniem gp130 
obserwowano znamiennie wyższe wartości glikemii (p = 0,04) i niższe stężenia IL-6 (p = 0,04) w porównaniu z kobietami z niskimi stęże-
niami IL-6R i sgp130. Obecność krążących IL-17 i IL-23 stwierdzono u około 1/3 spośród badanych kobiet. Wykazano również tendencję 
do wyższych stężeń IL-17 u pacjentek z cukrzycą ciążową, różnice nie były jednak istotne statystycznie.
Wnioski: Wyniki sugerują, że podwyższone stężenie gp130, obserwowane u kobiet z cukrzycą ciążową, może stanowić mechanizm 
kompensacyjny, zapobiegający nadmiernej aktywacji szlaku IL-6/IL-6R. (Endokrynol Pol 2014; 65 (3): 169–175)
Słowa kluczowe: IL-6; IL-6R; gp130; IL-17; IL-23; cukrzyca ciążowa
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Introduction
Interleukin-6 (IL-6) is a pleiotropic cytokine that 
regulates various physiological processes including 
inflammation, haematopoiesis, immune responses, and 
host defence mechanisms [1]. It signals through a cell 
surface type I cytokine receptor complex consisting of 
two subunits: a cognate receptor subunit (IL-6R), which 
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specifically recognises IL-6, and a signal-transducing 
element, the glycoprotein 130 (gp130) [2–4]. Soluble 
forms of IL-6R (sIL-6R) and gp130 (sgp130), which can 
be detected in the blood, are biologically active, but exert 
opposite functions. In the extracellular compartment, 
sIL-6R acts as an agonist to IL-6 by forming sIL-6R/ 
/IL-6 complex, which can bind to membrane gp130 and 
initiate the signal transduction that accounts for most 
of the biological activity of IL-6 [5]. In contrast, sgp130 
is considered an antagonist to the sIL-6R/IL-6 complex, 
preventing sIL-6R/IL-6 from binding to the membrane 
receptor [4, 6]. While IL-6 plasma levels change re-
markably over time, sIL-6R and sgp130 concentrations 
fluctuate much less, and give more precise information 
about the activation of IL-6 pathway [2, 4, 5]. Though 
characterised as both a pro- [7–9] and anti-inflammatory 
[10, 11] cytokine, IL-6 has been identified as a potential 
mediator linking chronic low-grade inflammation with 
insulin resistance [12]. Moreover, recent studies have 
shown that increased secretion of IL-6 can promote 
the differentiation of Th17 lymphocytes, resulting in 
elevated levels of IL-17 [13], which in turn promotes 
inflammation, triggering downstream nuclear factor-
kB and cytokine production [14–16]. Another main 
inducer of IL-17 seems to be monocyte and dendritic 
cell-derived IL-23 [16–18]. Conversely, adipocytes 
express significant levels of the IL-17 receptors and 
respond to IL-17 by secreting IL-6 [19]. 
In the last decade, elevated IL-6 levels have been 
repeatedly found in patients with gestational diabetes 
mellitus (GDM) compared to healthy pregnant women 
[20-23], strongly suggesting that IL-6 may contribute to 
the development of glucose intolerance during preg-
nancy. However, the IL-6 trans-signalling pathway, and 
in particular sgp130, has never been studied in patients 
with GDM. Therefore in the present study we analysed 
the IL-6/IL-6R/sgp130 system at different time points 
during and after pregnancy in relation to (i) the distur-
bances of glucose tolerance, (ii) the indices of insulin 
sensitivity and insulin secretion, and (iii) the levels of 
Th17 associated cytokines such as IL-17 and IL-23.
Material and methods
Study population
The group studied consisted of 91 pregnant women 
attending the gynaecological out-patient clinic of the 
Medical University of Bialystok and tested for GDM 
with a 75 g 2-h oral glucose tolerance test (OGTT) 
between the 24th and 28th week of gestation (visit 
1). GDM was diagnosed according to the criteria of 
the Polish Diabetological Association, with the fol-
lowing threshold glucose levels: fasting ≥ 100 mg/dL 
(5.5 mmol/L), 1 h ≥ 180 mg/dL (10.0 mmol/L) and 2 h 
≥ 140 mg/dL (7.8 mmol/L). In order to evaluate whether 
women who developed GDM in the 2nd trimester 
showed the same disturbances of insulin sensitivity and 
pro-inflammatory cytokines secretion as those who de-
veloped GDM in a late phase of pregnancy, the patients 
with NGT at the 1st visit were tested again four weeks 
later (visit 2). All tests were repeated three months after 
childbirth. Patients with multiple pregnancy, abnormal 
glucose readings before recruitment, or complications 
such as pregnancy-induced hypertension or pre-
eclampsia were excluded. Written informed consent 
was obtained from all participants, and the protocol 
was approved by the local ethics committee (Medical 
University of Bialystok). 
Analytical methods
The OGTT was performed after an overnight fast and 
blood samples were collected at 0, 30, 60 and 120 min after 
glucose load. Plasma glucose concentration was measured 
using the oxidase method (CORMAY, Poland), serum 
insulin was assayed by the immunoradiometric method 
(Biosource Europe SA, Belgium) and glycated haemoglo-
bin (HbA1c) was evaluated by a high performance liquid 
chromatography technique (BIO-RAD Laboratories, 
Germany). Total cholesterol, HDL-cholesterol, LDL-cho-
lesterol and triglyceride concentrations were measured by 
enzymatic methods (ANALCO-GBG, Poland). Serum IL-6, 
sIL-6R and sgp130 concentrations were measured using 
commercial immunoassays (Quantikine, R&D Systems, 
USA). Serum IL-17 and IL-23 levels were also assayed by 
ELISA (Biosource Europe SA, Belgium and Invitrogen, 
USA, respectively).
Insulin secretion and sensitivity calculation
The following indices of insulin sensitivity and secre-
tion were calculated:
 — the Matsuda and de Fronzo index (ISOGTT), defined 
as 10,000/√ [(FPG × FPI) × (G × I)], where FPG — 
fasting plasma glucose, FPI — fasting plasma insulin, 
G — mean glucose during the OGTT, and I — mean 
insulin (both calculated from glucose and insulin 
levels at 0, 30, and 120 min of the OGTT) [24];
 — two disposition indices as the products of insu-
lin sensitivity x insulin secretion (DI30 = ISOGTT × 
AUCIns30/AUCGlu30 and DI120 = ISOGTT x AUCIns120/ 
/AUCGlu120, where AUCIns30/AUCGlu30 — the ratio of the 
area under the insulin curve (AUC) to the area under 
the glucose curve during 0–30 min of the OGTT 
and AUCIns120/AUCGlu120 — the ratio of insulin AUC 
to glucose AUC during 0–120 min of the OGTT) [25, 
26]. The trapezoidal method was used to calculate 
glucose and insulin AUC during the OGTT;
 — the homeostasis model assessment of insulin resist-
ance (HOMA-IR) calculated as FPG × FPI/22.5 [27].
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Statistical analysis
The data was analysed by the STATISTICA 10.0 for 
Windows Software (StatSoft.Inc, Tulsa, OK, USA). Be-
fore analysis, data was tested for normality of distribu-
tion using the Shapiro-Wilk test. Differences between 
the groups were compared by Mann-Whitney U test, 
and relationships between variables were tested by 
Spearman’s rank correlations. One-way ANOVA with 
Bonferroni correction was used to compare the differ-
ences in interleukin concentrations during the course 
of pregnancy, after log-transformation of non-normally 
distributed variables. A p value of less than 0.05 was 
regarded as statistically significant. 
Results
Clinical characteristics of the groups studied
The clinical characteristics of the groups studied are 
summarised in Table I. On the basis of the OGTT, the pa-
tients were divided into three groups: GDM at the first 
visit (GDM1, n = 24), normal glucose tolerance at the 
1st visit and GDM at the 2nd visit (GDM2, n = 22), and 
the patients with normal glucose tolerance at the first 
visit who remained so four weeks later (NGT, n = 45).
The patients from the GDM1 group had significantly 
higher glucose and insulin at 120 min of the OGTT 
(p < 0.00001 and p = 0.002, respectively), and higher tri-
glyceride concentrations (p = 0.03), as well as lower ISOGTT 
(p = 0.03), DI30 (p = 0.0005) and DI120 (p = 0.0005) than 
had the women with NGT. At the 1st visit the women 
classified as having NGT after the first OGTT but who 
later developed GDM (GDM2), had markedly higher 
glucose at 120 min of the OGTT (p = 0.02), fasting and 
post-load insulin (p = 0.006 and p = 0.04, respectively), 
higher HbA1c (p = 0.04), HOMA-IR (p = 0.01) and 
triglyceride concentration (p = 0.006), as well as lower 
DI30 (p = 0.02) and DI120 (p = 0.02) compared to the 
subjects with NGT throughout pregnancy. The patients 
with GDM recognised at the 2nd visit had significantly 
higher fasting (p = 0.02) and 120 min. OGTT glucose 
levels (p < 0.00001), higher fasting and post load in-
sulin (p = 0.03 and p = 0.004, respectively), higher 
HOMA-IR (p = 0.001), as well as markedly lower ISOGTT 
(p = 0.003), DI30 (p = 0.0009) and DI120 (p = 0.0002) than 
had the women with NGT. Three months postpartum, 
there were no significant differences in anthropometric 
and metabolic variables between the patients with and 
without GDM in pregnancy. 
The levels of IL-6/sIL-6R/sgp130 and Th17 associated 
cytokines in patients with and without GDM
At the first visit, the patients from the GDM1 group 
had significantly higher IL-6 (p = 0.02) and sgp130 
(p = 0.03) concentrations than had the women with 
NGT (Table II). The women with low sIL-6R (below 
median value) and high sgp130 concentration had 
significantly higher fasting and 120’ postload glucose 
levels (p = 0.04), as well as lower DI30 (p = 0.02) and 
IL-6 values (p = 0.04) than had the patients with low 
sIL-6R and sgp130 concentrations.
At the 1st visit, IL-17 was detected in 35.5% of the 
women with NGT, 42% of the patients with GDM and 
23% of the women with normal result of the 1st OGTT 
who later developed GDM (GDM2). The highest level 
of IL-17 was found in the GDM1 group, but the differ-
ence was not significant. IL-23 was detected in 31% of 
the subjects with NGT, 17% of the patients with GDM 
and 41% of the subjects with normal glucose tolerance 
after the 1st OGTT who later developed GDM. At the 
1st visit, the lowest levels of IL-23 were observed in the 
GDM1 group (Table II).
At the 2nd visit, the women with GDM2 had mark-
edly higher sIL-6R levels (p = 0.03) compared to the 
NGT subjects. There was also a trend towards higher 
IL-6 levels in patients with GDM2, but the difference 
was not significant. The patients with comparatively 
high sgp130 and low sIL-6R levels had significantly 
higher HbA1c value (p = 0.04) and lower IL-6 
(p = 0.04) concentration compared to the subjects with 
high sIL-6R and low sgp130 values.
At the 2nd visit, IL-17 was detected in 51% of the 
women with NGT and 64% of the women with GDM, 
whereas IL-23 was detected in 20% of the subjects with 
NGT and 35.5% of the patients with GDM. Median 
concentrations of both interleukins did not differ sig-
nificantly between the groups studied.
Three months postpartum, the women with previ-
ous GDM had significantly higher sgp130 concentra-
tions than had the women with NGT during pregnancy 
(p = 0.01), whereas other interleukins levels did not 
differ between the two groups (Table II). IL-17 and 
IL-23 were detected in 33% and 37% of the women with 
previous GDM, as well as in 22% and 35% of women 
with NGT in pregnancy, respectively.
Serum sIL-6R and sgp130 levels increased signifi-
cantly between the 1st and the 2nd visit in the GDM2 
group (p = 0.02 and p = 0.04, respectively), whereas in 
the subjects with NGT, sgp130 concentrations increased 
in the same period with a borderline significance 
(p = 0.057). In both groups there was also a trend towards 
higher IL-6 levels at the 2nd visit, but the differences 
were not significant. Three months postpartum, sgp130 
concentrations increased markedly in the women with 
previous GDM compared to the values observed in the 
3rd trimester (p = 0.04). There was also an increase in 
IL-23 concentrations in both groups — with and with-
out GDM – but the difference was significant only when 
all the patients were analysed together (p = 0.039).
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Correlations between serum levels of interleukins 
studied and other variables
At the 1st visit in the GDM1 group, there was a nega-
tive correlation between IL-6 concentration and DI30 
(R = –0.63, p = 0.03), as well as a positive correlation 
between sgp130 and IL-17 concentration (R = 0.79, 
p = 0.03). In the women with NGT, IL-6 and IL-23 levels 
correlated positively with HbA1c (R = 0.34, p = 0.04 
and R = 0.58, p = 0.01, respectively).
At the 2nd visit in the patients with GDM2, there 
was a negative correlation between IL-6 concentra-
tion and ISOGTT (R = –0.53, p = 0.01), whereas in the 
healthy pregnant women IL-6 concentration corre-
lated positively with HOMA-IR (R = 0.54, p = 0.038), 
as well as negatively with DI30 (R = –0.54, p = 0.04) 
and DI120 (R = –0.68, p = 0.005). In the same group, 
sgp130 level correlated positively with HBA1c 
(R = 0.65 p = 0.006). 
Three months after childbirth in the patients 
with previous GDM, there was a positive correlation 
between IL-6 and IL-17 concentrations (R = 0.70, 
p = 0.03), whereas in the group with NGT during 
pregnancy IL-6 concentration correlated positively 
with fasting insulin (R = 0.72, p = 0.005) and HOMA-IR 
(R = 0.57, p = 0.04), as well as negatively with ISOGTT 
(R = –0.59, p = 0.03) and DI120 (R = –0.67, p = 0.01). In 
the same group sgp130 level correlated positively with 
HbA1c (R = 0.56, p = 0.04).
Discussion
In the last few years, it has been suggested that the pres-
ence of GDM is connected with decreased oestrogen 
receptors expression [28] and abnormal adipokines 
production by adipose tissue [29], elevated expression 
of adenosine receptors in leukocytes [30], and an imbal-
ance between circulating pro- and anti-inflammatory 
cytokines [20–23], but their contribution to the patho-
genesis of GDM remains unclear.
Our study showed that the patients with GDM 
recognised between the 24th–28th week of gestation 
had significantly higher IL-6 and sgp130 concentra-
tions than had the women with NGT, whereas the 
women with GDM diagnosed in the 29th–32nd week 
of pregnancy had elevated sIL-6R and an insignificant 
trend towards higher IL-6 levels. During the four 
weeks between the 1st and the 2nd visits, IL-6 and 
sgp130 concentrations rose in both groups studied, 
whereas sIL-6R level increased only in the patients who 
developed GDM. Three months postpartum, sgp130 
concentrations increased markedly in the women with 
previous GDM compared to the values observed in the 
3rd trimester and were significantly higher than in the 
patients with NGT. Ta
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These results are in agreement with our previous 
findings [21, 22, 31], as well as with other studies [20, 23] 
consistently showing higher IL-6 levels in patients with 
GDM compared to healthy pregnant women. However, 
there is still some controversy regarding the source(s) 
of elevated IL-6 in GDM subjects. In our previous stud-
ies, there were no significant differences in IL-6 mRNA 
expression in fat and placental tissue obtained from the 
patients with and without GDM [31, 32]. Similarly, Lap-
pas et al. [33] did not find any marked differences in IL-6 
release from the placenta, adipose tissue and skeletal 
muscle of the women with GDM compared to the NGT 
subjects. In contrast, Kleiblova et al. [28] demonstrated 
higher IL-6 gene expression in subcutaneous adipose 
tissue from the patients with GDM. Furthermore, the 
causal relationship between IL-6, insulin resistance 
and GDM seems far from clear. It has been shown that 
chronic and acute IL-6 exposure causes impaired insu-
lin signalling in adipocytes [7, 8] and liver cells [9] but 
anti-inflammatory and insulin-sensitising effects of this 
cytokine have also been described [10, 11]. Although the 
cross-sectional design of our study limits any specula-
tion about a causal relationship between IL-6 and in-
sulin resistance, it is worth noting that in both groups 
studied, IL-6 concentration correlated negatively with 
the indices of insulin sensitivity and beta-cells response 
to pregnancy-induced insulin resistance. We should also 
mention that some authors have found elevated IL-6 
levels several months after childbirth in patients with 
previous GDM [23, 34], but the present study did not 
confirm this observation.
In contrast to IL-6, which has been extensively 
studied in pregnant women, the other elements of 
the IL-6 signalling pathway have never been assessed 
in GDM patients. This seems rather surprising since 
gp130 trans-signalling is considered to be critical for 
the regulation of IL-6 induced cellular response [2–4]. 
The present study showed elevated sgp130 serum levels 
in the patients with GDM both between the 24th–28th 
week of gestation and three months postpartum. Ad-
ditionally, in the group with NGT, sgp130 concentration 
correlated positively with HbA1c values both during 
and after pregnancy. Moreover, the women with com-
paratively low sIL-6R and high sgp130 concentration 
had significantly lower IL-6 levels, as well as higher 
fasting and post-load glucose values and lower DI30, 
which is considered to be a measure of beta cell response 
to the certain level of insulin resistance [26]. Although 
there is no other data concerning sgp130 in GDM 
subjects, elevated sgp130 levels have been observed 
in various diseases connected with insulin resistance, 
such as metabolic syndrome [35] and polycystic ovary 
syndrome [36], as well as in pre-eclampsia [37]. On 
the basis of these findings, it can be hypothesised that 
in the presence of IL-6 mediated chronic low-grade 
inflammation, increased sgp130 levels might represent 
a compensatory mechanism controlling intracellular 
IL-6 signalling and preventing the activation of the IL-6/
Il-6R pathway. However, since there is good evidence 
that gp130 activators might be useful in the treatment 
of obesity and insulin resistance [38], the hypothesis 
that the inhibition of gp130 trans-signalling could pro-
mote insulin resistance cannot be excluded. Since in 
the present study all measurements were performed at 
two time points during pregnancy, we had an unique 
opportunity to assess the IL-6/IL-6R/gp130 system in 
the patients who were normoglycaemic at the time of 
sampling but later developed GDM; however, neither 
IL-6 nor sIL-6R and sgp130 levels were elevated in this 
group before the diagnosis of GDM. 
The next hypothesis tested in the present study was 
the assumption that increased secretion of IL-6 in GDM 
subjects may lead to a pro-Th17 skewing milieu [13], 
which in turn results in elevated levels of so-called Th17 
cytokines. Other studies have shown that the IL-17/IL-
23 axis is elevated in obese patients [39] and that IL-17 
is an important inhibitor of adipocyte differentiation 
and insulin-induced glucose uptake in adipose tissue 
[40]. In the present study, IL-17 was detected in 42% 
of the GDM subjects and in 35% of the women with 
NGT in the 2nd trimester, whereas four weeks later 
this percentage increased to 64% in the group with 
GDM and to 51% in the group with NGT. IL-23 was 
detected in approximately one third of the patients 
at both visits. There was also a trend towards higher 
IL-17 and — rather surprisingly — low IL-23 levels in 
the subjects with GDM in the 24th-28th week of gesta-
tion but the differences were not significant, probably 
due to a relatively small number of samples and large 
variations among the patients studied. Three months 
postpartum, IL-23 concentrations increased markedly, 
whereas IL-17 levels were comparable with the values 
observed during pregnancy. It is also worth noting 
that in the patients with previous GDM, IL-17 cor-
related positively with IL-6 concentration, suggesting 
a functional relationship between these two cytokines.
In conclusion, our results suggest that an increased 
sgp130 concentration observed in the patients with 
GDM might represent a compensatory mechanism 
controlling intracellular IL-6 signalling and preventing 
the activation of the IL-6/IL-6R pathway. 
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